194 results on '"Padhani, A.R."'
Search Results
2. Targeted with perilesional biopsy should be considered as the new standard for the diagnosis of clinically significant prostate cancer. A systemic review & meta-analysis
- Author
-
Sanguedolce, F., primary, Tedde, A., additional, Lauwers, C.N.G., additional, Panarello, M., additional, Basile, G., additional, Gallioli, A., additional, Berquin, C., additional, Pecoraro, A., additional, Robalino, J., additional, Bravo, A., additional, Massimo, M., additional, Baboudjian, M., additional, Schoots, I.G., additional, Padhani, A.R., additional, Palou, J., additional, and Breda, A., additional
- Published
- 2024
- Full Text
- View/download PDF
3. Sacral Insufficiency Fracture Following Pelvic Radiotherapy in Gynaecological Malignancies: Development of a Predictive Model
- Author
-
Mir, R., Dragan, A.D., Mistry, H.B., Tsang, Y.M., Padhani, A.R., and Hoskin, P.
- Published
- 2021
- Full Text
- View/download PDF
4. Likert vs PI-RADS v2 for reporting screening bpMRI: results from the IP-1 PROSTAGRAM study
- Author
-
Mayor, N., primary, Eldred-Evans, D., additional, Burak, P., additional, Connor, M.J., additional, Day, E., additional, Evans, M., additional, Fiorentino, F., additional, Gammon, M., additional, Hosking-Jervis, F., additional, Klimowska-Nassar, N., additional, McGuire, W., additional, Padhani, A.R., additional, Prevost, A.T., additional, Price, D., additional, Sokhi, H., additional, Tam, H., additional, Light, A.J.W., additional, Winkler M., M., additional, and Ahmed, H.U., additional
- Published
- 2023
- Full Text
- View/download PDF
5. PSA density reduces biopsy rates in a screening population: outcomes from the IP1-PROSTAGRAM study
- Author
-
Mayor, N., primary, Eldred-Evans, D., additional, Burak, P., additional, Connor, M.J., additional, Day, E., additional, Evans, M., additional, Fiorentino, F., additional, Gammon, M., additional, Hosking-Jervis, F., additional, Klimowska-Nassar, N., additional, McGuire, W., additional, Padhani, A.R., additional, Prevost, A.T., additional, Price, D., additional, Sokhi, H., additional, Tam, H., additional, Light, A.J.W., additional, Winkler M., M., additional, and Ahmed, H.U., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway.
- Author
-
Barrett, T., Rooij, M. de, Giganti, F., Allen, C., Barentsz, J.O., Padhani, A.R., Barrett, T., Rooij, M. de, Giganti, F., Allen, C., Barentsz, J.O., and Padhani, A.R.
- Abstract
01 januari 2023, Item does not contain fulltext, Multiparametric MRI of the prostate is now recommended as the initial diagnostic test for men presenting with suspected prostate cancer, with a negative MRI enabling safe avoidance of biopsy and a positive result enabling MRI-directed sampling of lesions. The diagnostic pathway consists of several steps, from initial patient presentation and preparation to performing and interpreting MRI, communicating the imaging findings, outlining the prostate and intra-prostatic target lesions, performing the biopsy and assessing the cores. Each component of this pathway requires experienced clinicians, optimized equipment, good inter-disciplinary communication between specialists, and standardized workflows in order to achieve the expected outcomes. Assessment of quality and mitigation measures are essential for the success of the MRI-directed prostate cancer diagnostic pathway. Quality assurance processes including Prostate Imaging-Reporting and Data System, template biopsy, and pathology guidelines help to minimize variation and ensure optimization of the diagnostic pathway. Quality control systems including the Prostate Imaging Quality scoring system, patient-level outcomes (such as Prostate Imaging-Reporting and Data System MRI score assignment and cancer detection rates), multidisciplinary meeting review and audits might also be used to provide consistency of outcomes and ensure that all the benefits of the MRI-directed pathway are achieved.
- Published
- 2023
7. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
- Author
-
Gillessen, S., Bossi, A., Davis, I.D., Bono, J. de, Fizazi, K., James, N.D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, E.S., Aparicio, A.M., Armstrong, A.J., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Blanchard, P., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Castellano, D., Castro, E., Cheng, H.H., Chi, K.N., Chowdhury, S., Clarke, C.S., Clarke, N., Daugaard, G., Santis, M. de, Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O. Ngozi, Evans, C.P., Fanti, S., Feng, F.Y., Fonteyne, V., Fossati, N., Frydenberg, M., George, D., Gleave, M., Gravis, G., Halabi, S., Heinrich, D., Herrmann, K., Higano, C., Hofman, M.S., Horvath, L.G., Hussain, M., Jereczek-Fossa, Barbara A., Jones, R., Kanesvaran, R., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Klotz, L., Kramer, G., Leibowitz, R., Logothetis, C.J., Mahal, B.A., Maluf, F. Cotait, Mateo, J., Matheson, D., Mehra, N., Merseburger, A., Morgans, A.K., Morris, M.J., Mrabti, H., Mukherji, D., Murphy, D.G.M., Murthy, V., Nguyen, P.L., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Pezaro, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M.A., Ryan, C.J., Saad, F., Sade, J. Pablo, Sartor, O.A., Scher, H.I., Sharifi, N., Skoneczna, I., Soule, H., Spratt, D.E., Srinivas, S., Sternberg, C.N., Steuber, T., Oort, I.M. van, Zilli, T., Omlin, A., Gillessen, S., Bossi, A., Davis, I.D., Bono, J. de, Fizazi, K., James, N.D., Mottet, N., Shore, N., Small, E., Smith, M., Sweeney, C., Tombal, B., Antonarakis, E.S., Aparicio, A.M., Armstrong, A.J., Attard, G., Beer, T.M., Beltran, H., Bjartell, A., Blanchard, P., Briganti, A., Bristow, R.G., Bulbul, M., Caffo, O., Castellano, D., Castro, E., Cheng, H.H., Chi, K.N., Chowdhury, S., Clarke, C.S., Clarke, N., Daugaard, G., Santis, M. de, Duran, I., Eeles, R., Efstathiou, E., Efstathiou, J., Ekeke, O. Ngozi, Evans, C.P., Fanti, S., Feng, F.Y., Fonteyne, V., Fossati, N., Frydenberg, M., George, D., Gleave, M., Gravis, G., Halabi, S., Heinrich, D., Herrmann, K., Higano, C., Hofman, M.S., Horvath, L.G., Hussain, M., Jereczek-Fossa, Barbara A., Jones, R., Kanesvaran, R., Kellokumpu-Lehtinen, P.L., Khauli, R.B., Klotz, L., Kramer, G., Leibowitz, R., Logothetis, C.J., Mahal, B.A., Maluf, F. Cotait, Mateo, J., Matheson, D., Mehra, N., Merseburger, A., Morgans, A.K., Morris, M.J., Mrabti, H., Mukherji, D., Murphy, D.G.M., Murthy, V., Nguyen, P.L., Oh, W.K., Ost, P., O'Sullivan, J.M., Padhani, A.R., Pezaro, C., Poon, D.M.C., Pritchard, C.C., Rabah, D.M., Rathkopf, D., Reiter, R.E., Rubin, M.A., Ryan, C.J., Saad, F., Sade, J. Pablo, Sartor, O.A., Scher, H.I., Sharifi, N., Skoneczna, I., Soule, H., Spratt, D.E., Srinivas, S., Sternberg, C.N., Steuber, T., Oort, I.M. van, Zilli, T., and Omlin, A.
- Abstract
Item does not contain fulltext, BACKGROUND: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. OBJECTIVE: To present consensus voting results for select questions from APCCC 2022. DESIGN, SETTING, AND PARTICIPANTS: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. RESULTS AND LIMITATIONS: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. CONCLUSIONS: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical manage
- Published
- 2023
8. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
- Author
-
Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P.S., Sartor, O., Smith, M.R., Soule, H.R., Akaza, H., Beer, T.M., Beltran, H., Chinnaiyan, A.M., Daugaard, G., Davis, I.D., De Santis, M., Drake, C.G., Eeles, R.A., Fanti, S., Gleave, M.E., Heidenreich, A., Hussain, M., James, N.D., Lecouvet, F.E., Logothetis, C.J., Mastris, K., Nilsson, S., Oh, W.K., Olmos, D., Padhani, A.R., Parker, C., Rubin, M.A., Schalken, J.A., Scher, H.I., Sella, A., Shore, N.D., Small, E.J., Sternberg, C.N., Suzuki, H., Sweeney, C.J., Tannock, I.F., and Tombal, B.
- Published
- 2015
- Full Text
- View/download PDF
9. Audit of cancer yields after prostate MRI using both the PI-RADS version 2 and Likert scoring systems
- Author
-
Sokhi, H.K., primary, Wilson, A., additional, Pindoria, N., additional, McNamara, C., additional, Padhani, A.R., additional, Meer, Z., additional, and Pope, A., additional
- Published
- 2022
- Full Text
- View/download PDF
10. Prostate MRI: Who, when, and how? Report from a UK consensus meeting
- Author
-
Kirkham, A.P.S., Haslam, P., Keanie, J.Y., McCafferty, I., Padhani, A.R., Punwani, S., Richenberg, J., Rottenberg, G., Sohaib, A., Thompson, P., Turnbull, L.W., Kurban, L., Sahdev, A., Clements, R., Carey, B.M., and Allen, C.
- Published
- 2013
- Full Text
- View/download PDF
11. Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021
- Author
-
Tilki, Derya, Gillessen, S.; Armstron, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.S.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Ekeke, O.N.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I., Yamoah, K.; Ye, D.; Zapatero, A.; Omlin, A., Koç University Hospital, School of Medicine, Tilki, Derya, Gillessen, S.; Armstron, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.S.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Ekeke, O.N.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I., Yamoah, K.; Ye, D.; Zapatero, A.; Omlin, A., Koç University Hospital, and School of Medicine
- Abstract
Background: innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. Objective: to present the voting results from APCCC 2021. Design, setting, and participants: the experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. Results and limitations: the voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: these voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical eviden, National Health and Medical Research Council (NHMRC) Practitioner Fellowship; Prostate Cancer Foundation; Peter MacCallum Foundation; NHMRC Investigator Grant
- Published
- 2022
12. What experts think about prostate cancer management during the COVID-19 pandemic: report from The Advanced Prostate Cancer Consensus Conference 2021
- Author
-
Tilki, Derya, Turco, F.; Armstrong, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ekeke, O.N.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.-E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I.; Yamoah, K.; Ye, D.; Zapatero, A.; Gillessen, S.; Omlin, A., Koç University Hospital, School of Medicine, Tilki, Derya, Turco, F.; Armstrong, A.; Attard, G.; Beer, T.M.; Beltran, H.; Bjartell, A.; Bossi, A.; Briganti, A.; Bristow, R.G.; Bulbul, M.; Caffo, O.; Chi, K.N.; Clarke, C.S.; Clarke, N.; Davis, I.D.; de Bono, J.; Duran, I.; Eeles, R.; Efstathiou, E.; Efstathiou, J.; Evans, C.P.; Fanti, S.; Feng, F.Y.; Fizazi, K.; Frydenberg, M.; George, D.; Gleave, M.; Halabi, S.; Heinrich, D.; Higano, C.; Hofman, M.S.; Hussain, M.; James, N.; Jones, R.; Kanesvaran, R.; Khauli, R.B.; Klotz, L.; Leibowitz, R.; Logothetis, C.; Maluf, F.; Millman, R.; Morgans, A.K.; Morris, M.J.; Mottet, N.; Mrabti, H.; Murphy, D.G.; Murthy, V.; Oh, W.K.; Ekeke, O.N.; Ost, P.; O'Sullivan, J.M.; Padhani, A.R.; Parker, C.; Poon, D.M.C.; Pritchard, C.C.; Rabah, D.M.; Rathkopf, D.; Reiter, R.E.; Rubin, M.; Ryan, C.J.; Saad, F.; Sade, J.P.; Sartor, O.; Scher, H.I.; Shore, N.; Skoneczna, I.; Small, E.; Smith, M.; Soule, H.; Spratt, D.E.; Sternberg, C.N.; Suzuki, H.; Sweeney, C.; Sydes, M.R.; Taplin, M.-E.; Tombal, B.; Türkeri, L.; Uemura, H.; Uemura, H.; van Oort, I.; Yamoah, K.; Ye, D.; Zapatero, A.; Gillessen, S.; Omlin, A., Koç University Hospital, and School of Medicine
- Abstract
Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive treatments, or comorbidities. Thus, the optimal management of APC patients during the COVID-19 pandemic is complex. In October 2021, during the Advanced Prostate Cancer Consensus Conference (APCCC) 2021, the 73 voting members of the panel members discussed and voted on 13 questions on this topic that could help clinicians make treatment choices during the pandemic. There was a consensus for full COVID-19 vaccination and booster injection in APC patients. Furthermore, the voting results indicate that the expert's treatment recommendations are influenced by the vaccination status: the COVID-19 pandemic altered management of APC patients for 70% of the panellists before the vaccination was available but only for 25% of panellists for fully vaccinated patients. Most experts (71%) were less likely to use docetaxel and abiraterone in unvaccinated patients with metastatic hormone-sensitive prostate cancer. For fully vaccinated patients with high-risk localised prostate cancer, there was a consensus (77%) to follow the usual treatment schedule, whereas in unvaccinated patients, 55% of the panel members voted for deferring radiation therapy. Finally, there was a strong consensus for the use of telemedicine for monitoring APC patients. Patient summary: In the Advanced Prostate Cancer Consensus Conference 2021, the panellists reached a consensus regarding the recommendation of the COVID-19 vaccine in prostate cancer patients and use of telemedicine for monitoring these patients., NA
- Published
- 2022
13. An evaluation of screening pathways using a combination of MRI and PSA: Results from the IP1-PROSTAGRAM study
- Author
-
Connor, M.J., primary, Eldred-Evans, D., additional, Tam, H., additional, Sokhi, H., additional, Padhani, A.R., additional, Price, D., additional, Gammon, M., additional, Klimowska-Nassar, N., additional, Burak, P., additional, Day, E., additional, Winkler, M., additional, Fiorentino, F., additional, and Ahmed, H.U., additional
- Published
- 2022
- Full Text
- View/download PDF
14. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021
- Author
-
Gillessen, S. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C.S. Clarke, N. Davis, I.D. de Bono, J.S. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Ekeke, O.N. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D.E. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M.R. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Omlin, A.
- Subjects
education - Abstract
Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but various areas of management still lack high-level evidence to inform clinical practice. The 2021 Advanced Prostate Cancer Consensus Conference (APCCC) addressed some of these questions to supplement guidelines that are based on level 1 evidence. Objective: To present the voting results from APCCC 2021. Design, setting, and participants: The experts identified three major areas of controversy related to management of advanced prostate cancer: newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), the use of prostate-specific membrane antigen ligands in diagnostics and therapy, and molecular characterisation of tissue and blood. A panel of 86 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 107 pre-defined questions, which were developed by both voting and non-voting panel members prior to the conference following a modified Delphi process. Results and limitations: The voting reflected the opinions of panellists and did not incorporate a standard literature review or formal meta-analysis. The answer options for the consensus questions received varying degrees of support from panellists, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: These voting results from a panel of experts in advanced prostate cancer can help clinicians and patients to navigate controversial areas of management for which high-level evidence is scant. However, diagnostic and treatment decisions should always be individualised according to patient characteristics, such as the extent and location of disease, prior treatment(s), comorbidities, patient preferences, and treatment recommendations, and should also incorporate current and emerging clinical evidence and logistic and economic constraints. Enrolment in clinical trials should be strongly encouraged. Importantly, APCCC 2021 once again identified salient questions that merit evaluation in specifically designed trials. Patient summary: The Advanced Prostate Cancer Consensus Conference is a forum for discussing current diagnosis and treatment options for patients with advanced prostate cancer. An expert panel votes on predefined questions focused on the most clinically relevant areas for treatment of advanced prostate cancer for which there are gaps in knowledge. The voting results provide a practical guide to help clinicians in discussing treatment options with patients as part of shared decision-making. © 2022 The Author(s)
- Published
- 2022
15. Corrigendum to 'What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021' [Eur Urol 82(1):6–11] (European Urology (2022) 82(1) (6–11), (S0302283822016505), (10.1016/j.eururo.2022.02.010))
- Author
-
Turco, F. Armstrong, A. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Bulbul, M. Caffo, O. Chi, K.N. Clarke, C. Clarke, N. Davis, I.D. de Bono, J. Duran, I. Eeles, R. Efstathiou, E. Efstathiou, J. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. George, D. Gleave, M. Halabi, S. Heinrich, D. Higano, C. Hofman, M.S. Hussain, M. James, N. Jones, R. Kanesvaran, R. Khauli, R.B. Klotz, L. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ekeke, O.N. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Rabah, D.M. Rathkopf, D. Reiter, R.E. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Skoneczna, I. Small, E. Smith, M. Soule, H. Spratt, D. Sternberg, C.N. Suzuki, H. Sweeney, C. Sydes, M. Taplin, M.-E. Tilki, D. Tombal, B. Türkeri, L. Uemura, H. Uemura, H. van Oort, I. Yamoah, K. Ye, D. Zapatero, A. Gillessen, S. Omlin, A.
- Abstract
The authors regret that Axel Heidenreich was added to the author list in error. The author list is now corrected as above, however the affiliations of remaining authors have been retained. The authors would like to apologise for any inconvenience caused. © 2022 The Author(s)
- Published
- 2022
16. Functional imaging of tumors. Part 2
- Author
-
García Figueiras, R., Padhani, A.R., Vilanova, J.C., Goh, V., and Villalba Martín, C.
- Published
- 2010
- Full Text
- View/download PDF
17. Functional imaging of tumors. Part 1
- Author
-
García Figueiras, R., Padhani, A.R., Vilanova Busquets, J.C., Goh, V., and Villalba Martín, C.
- Published
- 2010
- Full Text
- View/download PDF
18. Imagen funcional tumoral. Parte 2
- Author
-
García Figueiras, R., Padhani, A.R., Vilanova, J.C., Goh, V., and Villalba Martín, C.
- Published
- 2010
- Full Text
- View/download PDF
19. Imagen funcional tumoral. Parte 1
- Author
-
García Figueiras, R., Padhani, A.R., Vilanova, J.C., Goh, V., and Villalba Martín, C.
- Published
- 2010
- Full Text
- View/download PDF
20. Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR): International Consensus -based Guidelines on Multiparametric Magnetic Resonance Imaging for Prostate Cancer Recurrence after Radiation Therapy and Radical Prostatectomy
- Author
-
Panebianco, V, Villeirs, G., Weinreb, J.C., Turkbey, B.I., Margolis, D.J., Richenberg, J., Schoots, I.G., Moore, C.M., Futterer, J.J., Macura, K.J., Oto, A., Bittencourt, L.K., Haider, M.A., Salomon, G., Tempany, C.M., Padhani, A.R., Barentsz, J.O., Panebianco, V, Villeirs, G., Weinreb, J.C., Turkbey, B.I., Margolis, D.J., Richenberg, J., Schoots, I.G., Moore, C.M., Futterer, J.J., Macura, K.J., Oto, A., Bittencourt, L.K., Haider, M.A., Salomon, G., Tempany, C.M., Padhani, A.R., and Barentsz, J.O.
- Abstract
Item does not contain fulltext, BACKGROUND: Imaging techniques are used to identify local recurrence of prostate cancer (PCa) for salvage therapy and to exclude metastases that should be addressed with systemic therapy. For magnetic resonance imaging (MRI), a reduction in the variability of acquisition, interpretation, and reporting is required to detect local PCa recurrence in men with biochemical relapse after local treatment with curative intent. OBJECTIVE: To propose a standardised method for image acquisition and assessment of PCa local recurrence using MRI after radiation therapy (RP) and radical prostatectomy (RT). EVIDENCE ACQUISITION: Prostate Imaging for Recurrence Reporting (PI-RR) was formulated using the existing literature. An international panel of experts conducted a nonsystematic review of the literature. The PI-RR system was created via consensus through a combination of face-to-face and online discussions. EVIDENCE SYNTHESIS: Similar to with PI-RADS, based on the best available evidence and expert opinion, the minimum acceptable MRI parameters for detection of recurrence after radiation therapy and radical prostatectomy are set. Also, a simplified and standardised terminology and content of the reports that use five assessment categories to summarise the suspicion of local recurrence (PI-RR) are designed. PI-RR scores of 1 and 2 are assigned to lesions with a very low and low likelihood of recurrence, respectively. PI-RR 3 is assigned if the presence of recurrence is uncertain. PI-RR 4 and 5 are assigned for a high and very high likelihood of recurrence, respectively. PI-RR is intended to be used in routine clinical practice and to facilitate data collection and outcome monitoring for research. CONCLUSIONS: This paper provides a structured reporting system (PI-RR) for MRI evaluation of local recurrence of PCa after RT and RP. PATIENT SUMMARY: A new method called PI-RR was developed to promote standardisation and reduce variations in the acquisition, interpretation, and reporting
- Published
- 2021
21. ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging
- Author
-
Penzkofer, T., Padhani, A.R., Turkbey, B., Haider, M.A., Huisman, H.J., Walz, J., Salomon, G., Schoots, I.G., Richenberg, J., Villeirs, G., Panebianco, V, Rouviere, O., Logager, V.B., Barentsz, J.O., Penzkofer, T., Padhani, A.R., Turkbey, B., Haider, M.A., Huisman, H.J., Walz, J., Salomon, G., Schoots, I.G., Richenberg, J., Villeirs, G., Panebianco, V, Rouviere, O., Logager, V.B., and Barentsz, J.O.
- Abstract
Contains fulltext : 245173.pdf (Publisher’s version ) (Open Access), Artificial intelligence developments are essential to the successful deployment of community-wide, MRI-driven prostate cancer diagnosis. AI systems should ensure that the main benefits of biopsy avoidance are delivered while maintaining consistent high specificities, at a range of disease prevalences. Since all current artificial intelligence / computer-aided detection systems for prostate cancer detection are experimental, multiple developmental efforts are still needed to bring the vision to fruition. Initial work needs to focus on developing systems as diagnostic supporting aids so their results can be integrated into the radiologists' workflow including gland and target outlining tasks for fusion biopsies. Developing AI systems as clinical decision-making tools will require greater efforts. The latter encompass larger multicentric, multivendor datasets where the different needs of patients stratified by diagnostic settings, disease prevalence, patient preference, and clinical setting are considered. AI-based, robust, standard operating procedures will increase the confidence of patients and payers, thus enabling the wider adoption of the MRI-directed approach for prostate cancer diagnosis. KEY POINTS: * AI systems need to ensure that the benefits of biopsy avoidance are delivered with consistent high specificities, at a range of disease prevalence. * Initial work has focused on developing systems as diagnostic supporting aids for outlining tasks, so they can be integrated into the radiologists' workflow to support MRI-directed biopsies. * Decision support tools require a larger body of work including multicentric, multivendor studies where the clinical needs, disease prevalence, patient preferences, and clinical setting are additionally defined.
- Published
- 2021
22. Fast Magnetic Resonance Imaging as a Viable Method for Directing the Prostate Cancer Diagnostic Pathway
- Author
-
Padhani, A.R., Schoots, I.G., Barentsz, J.O., Padhani, A.R., Schoots, I.G., and Barentsz, J.O.
- Abstract
Item does not contain fulltext
- Published
- 2021
23. PI-RADS Committee Position on MRI Without Contrast Medium in Biopsy-Naive Men With Suspected Prostate Cancer: Narrative Review
- Author
-
Schoots, I.G., Barentsz, J.O., Bittencourt, L.K., Haider, M.A., Macura, K.J., Margolis, D.J., Moore, C.M., Oto, A., Panebianco, V, Siddiqui, M.M., Tempany, C., Turkbey, B., Villeirs, G.M., Weinreb, J.C., Padhani, A.R., Schoots, I.G., Barentsz, J.O., Bittencourt, L.K., Haider, M.A., Macura, K.J., Margolis, D.J., Moore, C.M., Oto, A., Panebianco, V, Siddiqui, M.M., Tempany, C., Turkbey, B., Villeirs, G.M., Weinreb, J.C., and Padhani, A.R.
- Abstract
Item does not contain fulltext, The steadily increasing demand for diagnostic prostate MRI has led to concerns regarding the lack of access to and the availability of qualified MRI scanners and sufficiently experienced radiologists, radiographers, and technologists to meet the demand. Solutions must enhance operational benefits without compromising diagnostic performance, quality, and delivery of service. Solutions should also mitigate risks such as decreased reader confidence and referrer engagement. One approach may be the implementation of MRI without the use gadolinium-based contrast medium (bipara-metric MRI), but only if certain prerequisites such as high-quality imaging, expert interpretation quality, and availability of patient recall or on-table monitoring are mandated. Alternatively, or in combination, a clinical risk-based approach could be used for protocol selection, specifically, which biopsy-naive men need MRI with contrast medium (multiparametric MRI). There is a need for prospective studies in which biopsy decisions are made according to MRI without contrast enhancement. Such studies must define clinical and operational benefits and identify which patient groups can be scanned successfully without contrast enhancement. These higher-quality data are needed before the Prostate Imaging Reporting and Data System (PI-RADS) Committee can make evidence-based recommendations about MRI without contrast enhancement as an initial diagnostic approach for prostate cancer workup.
- Published
- 2021
24. A multifaceted approach to quality in the MRI-directed biopsy pathway for prostate cancer diagnosis
- Author
-
Padhani, A.R., Schoots, I.G., Turkbey, B., Giannarini, G., Barentsz, J.O., Padhani, A.R., Schoots, I.G., Turkbey, B., Giannarini, G., and Barentsz, J.O.
- Abstract
Contains fulltext : 235571.pdf (Publisher’s version ) (Closed access), KEY POINTS: * Identify, assure, and measure major sources of variability affecting the MRI-directed biopsy pathway for prostate cancer diagnosis.* Develop strategies to control and minimize variations that impair pathway effectiveness including the performance of main players and team working.* Assure end-to-end quality of the diagnostic chain with robust multidisciplinary team working.
- Published
- 2021
25. Oral 39 - Likert vs PI-RADS v2 for reporting screening bpMRI: results from the IP-1 PROSTAGRAM study
- Author
-
Mayor, N., Eldred-Evans, D., Burak, P., Connor, M.J., Day, E., Evans, M., Fiorentino, F., Gammon, M., Hosking-Jervis, F., Klimowska-Nassar, N., McGuire, W., Padhani, A.R., Prevost, A.T., Price, D., Sokhi, H., Tam, H., Light, A.J.W., Winkler M., M., and Ahmed, H.U.
- Published
- 2023
- Full Text
- View/download PDF
26. Oral 40 - PSA density reduces biopsy rates in a screening population: outcomes from the IP1-PROSTAGRAM study
- Author
-
Mayor, N., Eldred-Evans, D., Burak, P., Connor, M.J., Day, E., Evans, M., Fiorentino, F., Gammon, M., Hosking-Jervis, F., Klimowska-Nassar, N., McGuire, W., Padhani, A.R., Prevost, A.T., Price, D., Sokhi, H., Tam, H., Light, A.J.W., Winkler M., M., and Ahmed, H.U.
- Published
- 2023
- Full Text
- View/download PDF
27. Stellenwert der multiparametrischen Magnetresonanztomographie beim Prostatakarzinom
- Author
-
Fueger, B.J., Helbich, T.H., Schernthaner, M., Zbýň, Š., Linhart, H.-G., Stiglbauer, A., Doan, A., Pinker, K., Heinz, G., Padhani, A.R., and Brader, P.
- Published
- 2011
- Full Text
- View/download PDF
28. Detection and Characterization of Musculoskeletal Cancer Using Whole-Body Magnetic Resonance Imaging
- Author
-
Isaac, A. Lecouvet, F. Dalili, D. Fayad, L. Pasoglou, V. Papakonstantinou, O. Ahlawat, S. Messiou, C. Weber, M.-A. Padhani, A.R.
- Abstract
Whole-body magnetic resonance imaging (WB-MRI) is gradually being integrated into clinical pathways for the detection, characterization, and staging of malignant tumors including those arising in the musculoskeletal (MSK) system. Although further developments and research are needed, it is now recognized that WB-MRI enables reliable, sensitive, and specific detection and quantification of disease burden, with clinical applications for a variety of disease types and a particular application for skeletal involvement. Advances in imaging techniques now allow the reliable incorporation of WB-MRI into clinical pathways, and guidelines recommending its use are emerging. This review assesses the benefits, clinical applications, limitations, and future capabilities of WB-MRI in the context of other next-generation imaging modalities, as a qualitative and quantitative tool for the detection and characterization of skeletal and soft tissue MSK malignancies. © 2020 BMJ Publishing Group. All rights reserved.
- Published
- 2020
29. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]
- Author
-
Gillessen, S. Attard, G. Beer, T.M. Beltran, H. Bjartell, A. Bossi, A. Briganti, A. Bristow, R.G. Chi, K.N. Clarke, N. Davis, I.D. de Bono, J. Drake, C.G. Duran, I. Eeles, R. Efstathiou, E. Evans, C.P. Fanti, S. Feng, F.Y. Fizazi, K. Frydenberg, M. Gleave, M. Halabi, S. Heidenreich, A. Heinrich, D. Higano, C.T.S. Hofman, M.S. Hussain, M. James, N. Kanesvaran, R. Kantoff, P. Khauli, R.B. Leibowitz, R. Logothetis, C. Maluf, F. Millman, R. Morgans, A.K. Morris, M.J. Mottet, N. Mrabti, H. Murphy, D.G. Murthy, V. Oh, W.K. Ost, P. O'Sullivan, J.M. Padhani, A.R. Parker, C. Poon, D.M.C. Pritchard, C.C. Reiter, R.E. Roach, M. Rubin, M. Ryan, C.J. Saad, F. Sade, J.P. Sartor, O. Scher, H.I. Shore, N. Small, E. Smith, M. Soule, H. Sternberg, C.N. Steuber, T. Suzuki, H. Sweeney, C. Sydes, M.R. Taplin, M.-E. Tombal, B. Türkeri, L. van Oort, I. Zapatero, A. Omlin, A.
- Abstract
At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019, 10 important areas of controversy in advanced prostate cancer management were identified and discussed, and experts voted on 123 predefined consensus questions. The full report of the results is summarised here. © 2020 The Authors Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence. Objective: To present the results from the APCCC 2019. Design, setting, and participants: Similar to prior conferences, experts identified 10 important areas of controversy regarding the management of advanced prostate cancer: locally advanced disease, biochemical recurrence after local therapy, treating the primary tumour in the metastatic setting, metastatic hormone-sensitive/naïve prostate cancer, nonmetastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, bone health and bone metastases, molecular characterisation of tissue and blood, inter- and intrapatient heterogeneity, and adverse effects of hormonal therapy and their management. A panel of 72 international prostate cancer experts developed the programme and the consensus questions. Outcome measurements and statistical analysis: The panel voted publicly but anonymously on 123 predefined questions, which were developed by both voting and nonvoting panel members prior to the conference following a modified Delphi process. Results and limitations: Panellists voted based on their opinions rather than a standard literature review or formal meta-analysis. The answer options for the consensus questions had varying degrees of support by the panel, as reflected in this article and the detailed voting results reported in the Supplementary material. Conclusions: These voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse. However, diagnostic and treatment decisions should always be individualised based on patient-specific factors, such as disease extent and location, prior lines of therapy, comorbidities, and treatment preferences, together with current and emerging clinical evidence and logistic and economic constraints. Clinical trial enrolment for men with advanced prostate cancer should be strongly encouraged. Importantly, APCCC 2019 once again identified important questions that merit assessment in specifically designed trials. Patient summary: The Advanced Prostate Cancer Consensus Conference provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference, which has been held three times since 2015, aims to share the knowledge of world experts in prostate cancer management with health care providers worldwide. At the end of the conference, an expert panel discusses and votes on predefined consensus questions that target the most clinically relevant areas of advanced prostate cancer treatment. The results of the voting provide a practical guide to help clinicians discuss therapeutic options with patients as part of shared and multidisciplinary decision making. © 2020 The Authors
- Published
- 2020
30. Focus on the Quality of Prostate Multiparametric Magnetic Resonance Imaging: Synopsis of the ESUR/ESUI Recommendations on Quality Assessment and Interpretation of Images and Radiologists' Training
- Author
-
Rooij, M. de, Israël, B., Barrett, T., Giganti, F., Padhani, A.R., Panebianco, V, Richenberg, J., Salomon, G., Schoots, I.G., Villeirs, G., Walz, J., Barentsz, J.O., Rooij, M. de, Israël, B., Barrett, T., Giganti, F., Padhani, A.R., Panebianco, V, Richenberg, J., Salomon, G., Schoots, I.G., Villeirs, G., Walz, J., and Barentsz, J.O.
- Abstract
Contains fulltext : 225861.pdf (Publisher’s version ) (Closed access)
- Published
- 2020
31. Re: Variability of the Positive Predictive Value of PI-RADS for Prostate MRI Across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel
- Author
-
Padhani, A.R., Barentsz, J., Weinreb, J., Schoots, I., Tempany, C., Padhani, A.R., Barentsz, J., Weinreb, J., Schoots, I., and Tempany, C.
- Abstract
Contains fulltext : 225775.pdf (Publisher’s version ) (Closed access)
- Published
- 2020
32. Platinum Opinion Counterview: The Evidence Base for the Benefit of Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis is Sound
- Author
-
Padhani, A.R., Villeirs, G., Ahmed, H.U., Panebianco, V, Schoots, I.G., Tempany, C.M., Weinreb, J., Barentsz, J.O., Padhani, A.R., Villeirs, G., Ahmed, H.U., Panebianco, V, Schoots, I.G., Tempany, C.M., Weinreb, J., and Barentsz, J.O.
- Abstract
Contains fulltext : 225907.pdf (Publisher’s version ) (Closed access)
- Published
- 2020
33. Analysis of Magnetic Resonance Imaging-directed Biopsy Strategies for Changing the Paradigm of Prostate Cancer Diagnosis
- Author
-
Schoots, I.G., Padhani, A.R., Rouviere, O., Barentsz, J.O., Richenberg, J., Schoots, I.G., Padhani, A.R., Rouviere, O., Barentsz, J.O., and Richenberg, J.
- Abstract
Contains fulltext : 219641.pdf (Publisher’s version ) (Closed access), BACKGROUND: The use of a magnetic resonance imaging (MRI)-directed diagnostic pathway in men at first prostate cancer work-up has been introduced within European prostate cancer guidelines. Differences in MRI-directed pathway yields need elaboration. OBJECTIVE: To investigate the diagnostic yields of MRI-directed diagnostic pathways in biopsy-naive men suspected of having prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: This analysis uses the data of the Cochrane diagnostic test accuracy systematic review on the utility of prostate MRI and MRI-targeted biopsy for significant disease in men at first diagnosis. The paired agreement analysis data were reformulated for five unique biopsy strategies focusing on diagnostic yields and biopsy avoidance. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Significant prostate cancer was defined as International Society of Urological Pathology (ISUP) grade group >/=2. RESULTS AND LIMITATIONS: The detection-focused pathway maximises the detection of significant disease (28% [95% confidence interval {CI} 24-34%]), while not reducing biopsy or core numbers, or the overdiagnoses of insignificant cancers (21% [18-25%]). The triage-focused pathway omits systematic biopsy use (reduction of 100%) and thereby reduces overdiagnoses of ISUP grade group 1 cancers (to 14% [11-17%]), but compromises the detection of significant disease (23% [19-28%]). The MRI-focused pathway maximises the detection of significant disease in MRI-positive men at a cost of nondetection of significant disease in MRI-negative men, thus reducing biopsies and overdiagnoses of ISUP grade 1 (strategy proposed by European Association of Urology guidelines). CONCLUSIONS: All MRI-directed biopsy pathways have beneficial outcomes compared with conventional systematic biopsy, with potentially reduced risks and harms. MRI-directed biopsy management as the default strategy optimises diagnostic yields in men at first diagnosis and may be the only test required in a significa
- Published
- 2020
34. Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review
- Author
-
Stabile, A., Giganti, F., Kasivisvanathan, V, Giannarini, G., Moore, C.M., Padhani, A.R., Panebianco, V, Rosenkrantz, A.B., Salomon, G., Turkbey, B., Villeirs, G., Barentsz, J.O., Stabile, A., Giganti, F., Kasivisvanathan, V, Giannarini, G., Moore, C.M., Padhani, A.R., Panebianco, V, Rosenkrantz, A.B., Salomon, G., Turkbey, B., Villeirs, G., and Barentsz, J.O.
- Abstract
Contains fulltext : 220776.pdf (Publisher’s version ) (Closed access), CONTEXT: There is a lack of comprehensive data regarding the factors that influence the diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI) to detect and localize clinically significant prostate cancer (csPCa). OBJECTIVE: To systematically review the current literature assessing the factors influencing the variability of mpMRI performance in csPCa diagnosis. EVIDENCE ACQUISITION: A computerized bibliographic search of Medline/PubMed database was performed for all studies assessing magnetic field strength, use of an endorectal coil, assessment system used by radiologists and inter-reader variability, experience of radiologists and urologists, use of a contrast agent, and use of computer-aided diagnosis (CAD) tools in relation to mpMRI diagnostic accuracy. EVIDENCE SYNTHESIS: A total of 77 articles were included. Both radiologists' reading experience and urologists'/radiologists' biopsy experience were the main factors that influenced diagnostic accuracy. Therefore, it is mandatory to indicate the experience of the interpreting radiologists and biopsy-performing urologists to support the reliability of the findings. The most recent Prostate Imaging Reporting and Data System (PI-RADS) guidelines are recommended for use as the main assessment system for csPCa, given the simplified and standardized approach as well as its particular added value for less experienced radiologists. Biparametric MRI had similar accuracy to mpMRI; however, biparametric MRI performed better with experienced readers. The limited data available suggest that the combination of CAD and radiologist readings may influence diagnostic accuracy positively. CONCLUSIONS: Multiple factors affect the accuracy of mpMRI and MRI-targeted biopsy to detect and localize csPCa. The high heterogeneity across the studies underlines the need to define the experience of radiologists and urologists, implement quality control, and adhere to the most recent PI-RADS assessment guidelines. Further re
- Published
- 2020
35. Diagnostic yields in patients with suspected prostate cancer undergoing MRI as the first-line investigation in routine practice
- Author
-
Sokhi, H.K., primary, Padhani, A.R., additional, Patel, S., additional, and Pope, A., additional
- Published
- 2020
- Full Text
- View/download PDF
36. 672P Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
- Author
-
Hijab, A., primary, Tunariu, N., additional, Tovey, H., additional, Alonzi, R., additional, Tree, A., additional, Staffurth, J., additional, Blackledge, M., additional, Padhani, A.R., additional, Stidwill, H., additional, Finch, J., additional, Chatfield, P., additional, Perry, S., additional, Koh, D-M., additional, Hall, E., additional, and Parker, C., additional
- Published
- 2020
- Full Text
- View/download PDF
37. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
- Author
-
Gillessen, S., primary, Omlin, A., additional, Attard, G., additional, de Bono, J.S., additional, Efstathiou, E., additional, Fizazi, K., additional, Halabi, S., additional, Nelson, P.S., additional, Sartor, O., additional, Smith, M.R., additional, Soule, H.R., additional, Akaza, H., additional, Beer, T.M., additional, Beltran, H., additional, Chinnaiyan, A.M., additional, Daugaard, G., additional, Davis, I.D., additional, De Santis, M., additional, Drake, C.G., additional, Eeles, R.A., additional, Fanti, S., additional, Gleave, M.E., additional, Heidenreich, A., additional, Hussain, M., additional, James, N.D., additional, Lecouvet, F.E., additional, Logothetis, C.J., additional, Mastris, K., additional, Nilsson, S., additional, Oh, W.K., additional, Olmos, D., additional, Padhani, A.R., additional, Parker, C., additional, Rubin, M.A., additional, Schalken, J.A., additional, Scher, H.I., additional, Sella, A., additional, Shore, N.D., additional, Small, E.J., additional, Sternberg, C.N., additional, Suzuki, H., additional, Sweeney, C.J., additional, Tannock, I.F., additional, and Tombal, B., additional
- Published
- 2019
- Full Text
- View/download PDF
38. IMAGING OF PHARMACODYNAMIC END POINTS IN CLINICAL TRIALS
- Author
-
ABOAGYE, ERIC O., primary, PRICE, PATRICIA M., additional, and Padhani, A.R., additional
- Published
- 2006
- Full Text
- View/download PDF
39. CONTRIBUTORS
- Author
-
Aboagye, Eric O., primary, Adjei, Alex A., additional, Albright, Charles F., additional, Ameyaw, Margaret-Mary, additional, Arbuck, Susan G., additional, Bonner, James A., additional, Buolamwini, John K., additional, Celis, Esteban, additional, Eisenhauer, Elizabeth, additional, Galanis, Evanthia, additional, Huang, Pearl S., additional, Huang, Ying, additional, Hunsberger, Sally A, additional, Kaminski, James J., additional, Kelland, Lloyd R., additional, Korn, Edward L., additional, Kusnezow, W., additional, Markovic, Svetomir N., additional, Mcleod, Howard L., additional, Nees, M., additional, Ove, Roger, additional, Padhani, A.R., additional, Pazdur, Richard, additional, Pluda, James M., additional, Powers, Robert, additional, Price, Patricia M., additional, Quella, Susan, additional, Rubinstein, Larry V., additional, Sheikh, M. Saeed, additional, Siegel, Marshall M., additional, Wang, Hui, additional, Williams, Grant, additional, Wissel, Paul S., additional, Woodworth, C.D., additional, and Zhang, Ruiwen, additional
- Published
- 2006
- Full Text
- View/download PDF
40. Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: What We See and What We Miss
- Author
-
Padhani, A.R., Haider, M.A., Villers, A., Barentsz, J.O., Padhani, A.R., Haider, M.A., Villers, A., and Barentsz, J.O.
- Abstract
Contains fulltext : 205506.pdf (publisher's version ) (Closed access)
- Published
- 2019
41. Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions
- Author
-
Padhani, A.R., Weinreb, J., Rosenkrantz, A.B., Villeirs, G., Turkbey, B., Barentsz, J., Padhani, A.R., Weinreb, J., Rosenkrantz, A.B., Villeirs, G., Turkbey, B., and Barentsz, J.
- Abstract
Contains fulltext : 203381.pdf (publisher's version ) (Open Access), CONTEXT: The Prostate Imaging-Reporting and Data System (PI-RADS) v2 analysis system for multiparametric magnetic resonance imaging (mpMRI) detection of prostate cancer (PCa) is based on PI-RADS v1, accumulated scientific evidence, and expert consensus opinion. OBJECTIVE: To summarize the accuracy, strengths and weaknesses of PI-RADS v2, discuss pathway implications of its use and outline opportunities for improvements and future developments. EVIDENCE ACQUISITION: For this consensus expert opinion from the PI-RADS steering committee, clinical studies, systematic reviews, and professional guidelines for mpMRI PCa detection were evaluated. We focused on the performance characteristics of PI-RADS v2, comparing data to systems based on clinicoradiologic Likert scales and non-PI-RADS v2 imaging only. Evidence selections were based on high-quality, prospective, histologically verified data, with minimal patient selection and verifications biases. EVIDENCE SYNTHESIS: It has been shown that the test performance of PI-RADS v2 in research and clinical practice retains higher accuracy over systematic transrectal ultrasound (TRUS) biopsies for PCa diagnosis. PI-RADS v2 fails to detect all cancers but does detect the majority of tumors capable of causing patient harm, which should not be missed. Test performance depends on the definition and prevalence of clinically significant disease. Good performance can be attained in practice when the quality of the diagnostic process can be assured, together with joint working of robustly trained radiologists and urologists, conducting biopsy procedures within multidisciplinary teams. CONCLUSIONS: It has been shown that the test performance of PI-RADS v2 in research and clinical practice is improved, retaining higher accuracy over systematic TRUS biopsies for PCa diagnosis. PATIENT SUMMARY: Multiparametric magnetic resonance imaging (MRI) and MRI-directed biopsies using the Prostate Imaging-Reporting and Data System improves the detection
- Published
- 2019
42. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2
- Author
-
Turkbey, B., Rosenkrantz, A.B., Haider, M.A., Padhani, A.R., Villeirs, G., Macura, K.J., Tempany, C.M., Choyke, P.L., Cornud, F., Margolis, D.J., Thoeny, H.C., Verma, S., Barentsz, J., Weinreb, J.C., Turkbey, B., Rosenkrantz, A.B., Haider, M.A., Padhani, A.R., Villeirs, G., Macura, K.J., Tempany, C.M., Choyke, P.L., Cornud, F., Margolis, D.J., Thoeny, H.C., Verma, S., Barentsz, J., and Weinreb, J.C.
- Abstract
Contains fulltext : 209078.pdf (publisher's version ) (Closed access), The Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) was developed with a consensus-based process using a combination of published data, and expert observations and opinions. In the short time since its release, numerous studies have validated the value of PI-RADS v2 but, as expected, have also identified a number of ambiguities and limitations, some of which have been documented in the literature with potential solutions offered. To address these issues, the PI-RADS Steering Committee, again using a consensus-based process, has recommended several modifications to PI-RADS v2, maintaining the framework of assigning scores to individual sequences and using these scores to derive an overall assessment category. This updated version, described in this article, is termed PI-RADS v2.1. It is anticipated that the adoption of these PI-RADS v2.1 modifications will improve inter-reader variability and simplify PI-RADS assessment of prostate magnetic resonance imaging even further. Research on the value and limitations on all components of PI-RADS v2.1 is strongly encouraged.
- Published
- 2019
43. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naive Men: The Next Step in Magnetic Resonance Imaging Accessibility
- Author
-
van der Leest, M., Israel, B., Cornel, E.B. (Erik), Zamecnik, P., Schoots, I.G. (Ivo), van der Lelij, H., Padhani, A.R., Rovers, M., van Oort, I., Sedelaar, M, Hulsbergen-van de Kaa, C.A. (Christina), Hannink, G., Veltman, J., Barentsz, J. (Jelle), van der Leest, M., Israel, B., Cornel, E.B. (Erik), Zamecnik, P., Schoots, I.G. (Ivo), van der Lelij, H., Padhani, A.R., Rovers, M., van Oort, I., Sedelaar, M, Hulsbergen-van de Kaa, C.A. (Christina), Hannink, G., Veltman, J., and Barentsz, J. (Jelle)
- Abstract
Background: To make magnetic resonance imaging (MRI) more accessible to men at risk of high-grade prostate cancer (PCa), there is a need for quicker, simpler, and less costly MRI protocols. Objective: To compare the diagnostic performance of monoplanar (“fast” biparametric MRI [bp-MRI]) and triplanar noncontrast bp-MRI with that of the current contrast-enhanced multiparametric MRI (mp-MRI) in the detection of high-grade PCa in biopsy-naïve men. Design, setting, and participants: A prospective, multireader, head-to-head study included 626 biopsy-naïve men, between February 2015 and February 2018. Intervention: Men underwent prebiopsy contrast-enhanced mp-MRI. Prior to biopsy, two blinded expert readers subsequently assessed “fast” bp-MRI, bp-MRI, and mp-MRI. Thereafter, systematic transrectal ultrasound-guided biopsies (SBs) were performed. Men with suspicious mp-MRI (Prostate Imaging Reporting and Data System 3–5 lesions) also underwent MR-in-bore biopsy (MRGB). Outcome measurements and statistical analysis: Primary outcome was the diagnostic performance of each protocol for the detection of high-grade PCa. Secondary outcomes included the difference in biopsy avoidance, detection of low-grade PCa, acquisition times, decision curve analyses, inter-reader agreement, and direct costs. Results from combined MRGB and SB were used as the reference standard. High-grade PCa was defined as grade 2. Results and limitations: Sensitivity for high-grade PCa for all protocols was 95% (180/ 190; 95% confidence interval [CI]: 91–97%). Specificity was 65% (285/436; 95% CI: 61–70%) for “fast” bp-MRI and 69% (299/436; 95% CI: 64–73%) for bp-MRI and mp-MRI. With fast bp-MRI, 0.96% (6/626) more low-grade PCa was detected. Biopsy could be avoided in 47% for the fast bp-MRI and in 49% for the bp-MRI and mp-MRI protocols. Fast bp-MRI and bp-MRI can be performed in 8 and 13 min, respectively, instead of 16 m
- Published
- 2019
- Full Text
- View/download PDF
44. A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus
- Author
-
Waters, J.S., Tait, D., Cunningham, D., Padhani, A.R., Hill, M.E., Falk, S., Lofts, F., Norman, A., Oates, J., and Hill, A.
- Published
- 2002
- Full Text
- View/download PDF
45. Functional MRI for anticancer therapy assessment
- Author
-
Padhani, A.R
- Published
- 2002
- Full Text
- View/download PDF
46. Consensus on molecular imaging and theranostics in prostate cancer
- Author
-
Fanti, S., Minozzi, S., Antoch, G., Banks, I., Briganti, A., Carrio, I., Chiti, A., Clarke, N., Eiber, M., Bono, J. de, Fizazi, K., Gillessen, S., Gledhill, S., Haberkorn, U., Herrmann, K., Hicks, R.J., Lecouvet, F., Montironi, R., Ost, P., O'Sullivan, J.M., Padhani, A.R., Schalken, J.A., Scher, H.I., Tombal, B., Moorselaar, R.J. van, Poppel, H. Van, Vargas, H.A., Walz, J., Weber, W.A., Wester, H.J., Oyen, W.J.G., Fanti, S., Minozzi, S., Antoch, G., Banks, I., Briganti, A., Carrio, I., Chiti, A., Clarke, N., Eiber, M., Bono, J. de, Fizazi, K., Gillessen, S., Gledhill, S., Haberkorn, U., Herrmann, K., Hicks, R.J., Lecouvet, F., Montironi, R., Ost, P., O'Sullivan, J.M., Padhani, A.R., Schalken, J.A., Scher, H.I., Tombal, B., Moorselaar, R.J. van, Poppel, H. Van, Vargas, H.A., Walz, J., Weber, W.A., Wester, H.J., and Oyen, W.J.G.
- Abstract
Contains fulltext : 200014.pdf (publisher's version ) (Closed access), Rapid developments in imaging and treatment with radiopharmaceuticals targeting prostate cancer pose issues for the development of guidelines for their appropriate use. To tackle this problem, international experts representing medical oncologists, urologists, radiation oncologists, radiologists, and nuclear medicine specialists convened at the European Association of Nuclear Medicine Focus 1 meeting to deliver a balanced perspective on available data and clinical experience of imaging in prostate cancer, which had been supported by a systematic review of the literature and a modified Delphi process. Relevant conclusions included the following: diphosphonate bone scanning and contrast-enhanced CT are mentioned but rarely recommended for most patients in clinical guidelines; MRI (whole-body or multiparametric) and prostate cancer-targeted PET are frequently suggested, but the specific contexts in which these methods affect practice are not established; sodium fluoride-18 for PET-CT bone scanning is not widely advocated, whereas gallium-68 or fluorine-18 prostate-specific membrane antigen gain acceptance; and, palliative treatment with bone targeting radiopharmaceuticals (rhenium-186, samarium-153, or strontium-89) have largely been replaced by radium-223 on the basis of the survival benefit that was reported in prospective trials, and by other systemic therapies with proven survival benefits. Although the advances in MRI and PET-CT have improved the accuracy of imaging, the effects of these new methods on clinical outcomes remains to be established. Improved communication between imagers and clinicians and more multidisciplinary input in clinical trial design are essential to encourage imaging insights into clinical decision making.
- Published
- 2018
47. Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L)
- Author
-
Taylor, S.A., Mallett, S., Miles, Anne, Beare, S., Bhatnagar, G., Bridgewater, J., Glynne-Jones, R., Goh, V., Groves, A.M., Janes, S.M., Koh, D.M., Morris, S., Morton, A., Navani, N., Oliver, A., Padhani, A.R., Punwani, S., Rockall, A.G., Halligan, S., and National Institute for Health Research
- Subjects
Patient experience ,Positron emission tomography ,Lung Neoplasms ,Staging ,Non-Randomized Controlled Trials as Topic ,Whole body magnetic resonance imaging ,lcsh:RC254-282 ,1117 Public Health and Health Services ,psyc ,Study Protocol ,Surveys and Questionnaires ,Humans ,Whole Body Imaging ,1112 Oncology and Carcinogenesis ,Prospective Studies ,Oncology & Carcinogenesis ,Computed tomography ,Neoplasm Staging ,Science & Technology ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Magnetic Resonance Imaging ,Colorectal cancer ,Oncology ,Patient Satisfaction ,METASTASIS ,Lung cancer ,Colorectal Neoplasms ,Life Sciences & Biomedicine - Abstract
Background and aims Rapid and accurate cancer staging following diagnosis underpins patient management, in particular the identification of distant metastatic disease. Current staging guidelines recommend sequential deployment of various imaging platforms such as computerised tomography (CT) and positron emission tomography (PET) which can be time and resource intensive and onerous for patients. Recent studies demonstrate that whole body magnetic resonance Imaging (WB-MRI) may stage cancer efficiently in a single visit, with potentially greater accuracy than current staging investigations. The Streamline trials aim to evaluate whether WB-MRI increases per patient detection of metastases in non-small cell lung and colorectal cancer compared to standard staging pathways. Methods The Streamline trials are multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies with a novel design to capture patient management decisions during staging pathways. The two trials recruit adult patients with proven or highly suspected new diagnosis of primary colorectal (Streamline C) or non-small cell lung cancer (Streamline L) referred for staging. Patients undergo WB-MRI in addition to standard staging investigations. Strict blinding protocols are enforced for those interpreting the imaging. A first major treatment decision is made by the multi-disciplinary team prior to WB-MRI revelation based on standard staging investigations only, then based on the WB-MRI and any additional tests precipitated by WB-MRI, and finally based on all available test results. The reference standard is derived by a multidisciplinary consensus panel who assess 12 months of follow-up data to adjudicate on the TNM stage at diagnosis. Health psychology assessment of patients’ experiences of the cancer staging pathway will be undertaken via interviews and questionnaires. A cost (effectiveness) analysis of WB-MRI compared to standard staging pathways will be performed. Discussion We describe a novel approach to radiologist and clinician blinding to ascertain the ‘true’ diagnostic accuracy of differing imaging pathways and discuss our approach to assessing the impact of WB-MRI on clinical decision making in real-time. The Streamline trials will compare WB-MRI and standard imaging pathways in the same patients, thereby informing the most accurate and efficient approach to staging. Trial registration Streamline C ISRCTN43958015 (registered 25/7/2012). Streamline L ISRCTN50436483 (registered 31/7/2012).
- Published
- 2017
- Full Text
- View/download PDF
48. Surgical restraint in the management of liver trauma
- Author
-
Watson, C.J.E., Calne, R.Y., Padhani, A.R., and Dixon, A.K.
- Subjects
Liver -- Wounds and injuries ,Wounds and injuries -- England ,Blunt trauma -- Care and treatment ,Health - Abstract
There is controversy over best treatment for liver injury. In England blunt injury to the liver is more common than penetrating injury (the reverse is true in the United States). Blunt injury has a worse prognosis than penetrating injury. A review is presented of 20 years' experience in treating patients with liver injury at one general hospital in England. A protocol for surgical treatment aimed at controlling bleeding from the liver is described. Eighty patients were treated between 1971 and 1990; 12 patients had computed tomographic evidence of liver injury and were initially observed (three patients eventually required surgery). Blunt abdominal injury was the cause of liver injury in 75 of the 80 patients treated. Motor vehicle accidents accounted for the majority of the injuries (57 of 75 blunt abdominal injuries). Possible treatment options included in the protocol were direct suture, liver artery ligation (tying off), or resection (removal of liver tissue); often the use of well-placed packing is enough to stop liver bleeding. Using this protocol 29 patients who had severe injuries were initially treated by placement of packing; this was later removed and surgery performed if required. Six of these patients later required surgery (hemihepatectomy, or removal of a portion of the liver). There were 39 patients who required immediate surgical exploration and definitive surgery; 11 of these patients died (28 percent). Of those treated by packing only, three patients died (10 percent). One death occurred in a patient who had been treated elsewhere using packing and died after being transferred to the university hospital. It is recommended that when patients are in stable condition, they should be assessed using computed tomographic scanning. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1991
49. Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study
- Author
-
Brown, J, Buckley, D, Coulthard, A, Dixon, A.K, Dixon, J.M, Easton, D.F, Eeles, R.A, Evans, D.G.R, Gilbert, F.G, Graves, M, Hayes, C, Jenkins, J.P.R, Jones, A.P, Keevil, S.F, Leach, M.O, Liney, G.P, Moss, S.M, Padhani, A.R, Parker, G.J.M, Pointon, L.J, Ponder, B.A.J, Redpath, T.W, Sloane, J.P, Turnbull, L.W, Walker, L.G, and Warren, R.M.L
- Published
- 2000
- Full Text
- View/download PDF
50. Response evaluation of cancer therapeutics in metastatic breast cancer to the bone: A single arm phase II study of whole-body magnetic resonance imaging
- Author
-
Kosmin, M., primary, Padhani, A.R., additional, Gogbashian, A., additional, Woolf, D., additional, Ah-See, M.-L., additional, Ostler, P., additional, Sutherland, S., additional, Miles, D., additional, Noble, J., additional, Marshall, A., additional, Dunn, J., additional, and Makris, A., additional
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.